Literature DB >> 11050093

Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains.

Y S Kim1, S P Cape, E Chi, R Raffen, P Wilkins-Stevens, F J Stevens, M C Manning, T W Randolph, A Solomon, J F Carpenter.   

Abstract

In primary (light chain-associated) amyloidosis, immunoglobulin light chains deposit as amyloid fibrils in vital organs, especially the kidney. Because the kidney contains high concentrations of urea that can destabilize light chains as well as solutes such as betaine and sorbitol that serve as protein stabilizers, we investigated the effects of these solutes on in vitro amyloid fibril formation and thermodynamic stability of light chains. Two recombinant light chain proteins, one amyloidogenic and the other nonamyloidogenic, were used as models. For both light chains, urea enhanced fibril formation by reducing the nucleation lag time and diminished protein thermodynamic stability. Conversely, betaine or sorbitol increased thermodynamic stability of the proteins and partially inhibited fibril formation. These solutes also counteracted urea-induced reduction in protein thermodynamic stability and accelerated fibril formation. Betaine was more effective than sorbitol. A model is presented to explain how the thermodynamic effects of the solutes on protein state equilibria can alter nucleation lag time and, hence, fibril formation kinetics. Our results provide evidence that renal solutes control thermodynamic and kinetic stability of light chains and thus may modulate amyloid fibril formation in the kidney.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11050093     DOI: 10.1074/jbc.M007766200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor.

Authors:  Eva Y Chi; Sampathkumar Krishnan; Brent S Kendrick; Byeong S Chang; John F Carpenter; Theodore W Randolph
Journal:  Protein Sci       Date:  2003-05       Impact factor: 6.725

Review 2.  Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation.

Authors:  Eva Y Chi; Sampathkumar Krishnan; Theodore W Randolph; John F Carpenter
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

3.  Size distribution of amyloid nanofibrils.

Authors:  Raffaela Cabriolu; Dimo Kashchiev; Stefan Auer
Journal:  Biophys J       Date:  2011-11-01       Impact factor: 4.033

4.  The effect of membranes on the in vitro fibrillation of an amyloidogenic light-chain variable-domain SMA.

Authors:  Xiaoyun Meng; Anthony L Fink; Vladimir N Uversky
Journal:  J Mol Biol       Date:  2008-06-28       Impact factor: 5.469

5.  High-pressure studies of aggregation of recombinant human interleukin-1 receptor antagonist: thermodynamics, kinetics, and application to accelerated formulation studies.

Authors:  Matthew B Seefeldt; Yong-Sung Kim; Kevin P Tolley; Jim Seely; John F Carpenter; Theodore W Randolph
Journal:  Protein Sci       Date:  2005-08-04       Impact factor: 6.725

Review 6.  Systemic amyloidoses.

Authors:  Luis M Blancas-Mejía; Marina Ramirez-Alvarado
Journal:  Annu Rev Biochem       Date:  2013-02-28       Impact factor: 23.643

Review 7.  Amyloid formation in light chain amyloidosis.

Authors:  Marina Ramirez-Alvarado
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

8.  Urea modulation of beta-amyloid fibril growth: experimental studies and kinetic models.

Authors:  Jin Ryoun Kim; Adrian Muresan; Ka Yee C Lee; Regina M Murphy
Journal:  Protein Sci       Date:  2004-09-30       Impact factor: 6.725

9.  Light chain amyloidosis - current findings and future prospects.

Authors:  Elizabeth M Baden; Laura A Sikkink; Marina Ramirez-Alvarado
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

10.  Buffer-dependent fragmentation of a humanized full-length monoclonal antibody.

Authors:  Branden A Salinas; Hasige A Sathish; Ambarish U Shah; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2010-07       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.